Publicaties
- Germonpré P, Janssens A, Van Moorter L, Verresen D, Galdermans D, Devogelaere R, Ottevaere H, Mentens Y, De Pooter C, Goor C. A Multicenter Phase II Study Of Carboplatin Plus Gemcitabine Followed By Concomitant Chemoradiation In Patients With Non-Resectable Stage III Non-Small-Cell-Lung Cancer: Preliminary Report of the Cher@Nos trial. 12th World Conference on Lung Cancer: P2-177. Download (pdf - 170 KB)
- Germonpré P, Janssens A, Van Moorter L, Verresen D, Galdermans D, Devogelaere R, Ottevaere H, Mentens Y, De Pooter C, Goor C. A Multicenter Phase II Trial Of Carboplatin And Gemcitabine Followed By Concurrent Chemoradiation In Patients With Unresectable Stage III Non-Small-Cell-Lung Cancer (NSCLC): FEV1 as Prognostic Marker. Am J Respir Crit Care Med 2008; vol 177: A311.
- Devogelaere R, Ottevaere H, Mentens Y, De Pooter C, Goor C. Multicenter Phase II Trial Of Carboplatin (Cb) And Gemcitabine (G) Followed By Concurrent Chemoradiation In Patients With Unresectable Stage III Non-Small-Cell-Lung Cancer (NSCLC): FEV1 as Prognostic Marker. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings Part I vol 26: 7558.
- Galdermans D., Driesen P., Bustin F., Lambrechts M., Deschepper K., Stappaerts I., Verresen D., Janssens A., Germonpré P. R. A randomized phase II feasibility study of adjuvant cisplatin/docetaxel (CisD) or cisplatin/vinorelbine (CisV) in patients (pts) resected stage IB-II non-small cell lung cancer (NSCLC): Interim analysis. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings Part I vol 26: 7594.
- Germonpré P, Janssens A, Van Moorter L, Verresen D, Galdermans D, Devogelaere R, Ottevaere H, Mentens Y, De Pooter Y, Goor C. Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial. Eur Respir J 2008 vol 32: 254S. Download (pdf - 50 KB)
- Germonpré P, Driesen P, Lambrechts M, Bosquée L, Bustin F, Verresen D, Galdermans D. Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis. Eur Respir J 2008, vol 32: 756S. Download (pdf - 37 KB)
- Germonpré P, Janssens A, Van Moorter L, Verresen D, Galdermans D, Devogelaere R, Ottevaere H, Mentens Y, De Pooter Y, Goor C. FEV1 As A Prognostic Factor For Survival In Stage III Nsclc Patients Treated With Chemoradiation: Multivariate Analysis Of Cher@nos Trial. Chest Meeting Abstracts 2008; vol 134: p45004. Download (pdf - 79 KB)
- Germonpré P, Janssens A, Galdermans D, Ortmanns P, Deschepper K, Devogelaere R, De Droogh E, De Pooter C, Goor C. A Randomized Multicenter Phase II Study Of Concurrent Pemetrexed And Radiotherapy With Induction Or Adjuvant Cisplatin/Pemetrexed In Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2009, 4 suppl 1: S853.
- Germonpré P, Janssens A, Nowé V, Boeykens E, De Pooter C, Goor C. FEV1 as prognostic marker in stage III non-small cell (NSCLC) patients treated with chemoradiation: pooled analysis of two multicenter phase II trials. J Thorac Oncol 2010, 5 (suppl 7): S518.
- Germonpré P, De Droogh E, Lefebure A, Kockx M, Pauwels P, Janssens A. Implementation Of EGFR Mutation Testing In Antwerp, Belgium: The HERMES-Project. Am J Respir Crit Care Med 2012, vol 185: A2523. Download (pdf - 37 KB)
- Janssens A, De Droogh E, Lefebure A, Kockx M, Pauwels P, Germonpre P, van Meerbeeck JP, Routine implementation of EGFR mutation testing in clinical practice in Flanders: 'HERMES' project. Acta Clin Belg. 2014 Apr;69(2):92-7 (pdf - 53 KB)